7,447.25

+45.25

+0.61%

51,761.00

+376.00

+0.73%

27,249.25

+164.00

+0.61%

Russell 2000 Futures

2,783.10

+22.60

+0.82%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,129.70

+54.80

+1.34%

74,785.56

-1,020.73

-1.35%

Crude Oil Dec 26

91.12

+0.29

+0.32%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqGS - Delayed Quote USD

Arrowhead Pharmaceuticals, Inc. (ARWR)

58.16 +0.70 (+1.22%)

At close: November 6 at 4:00:01 PM EST

58.16 +0.01 (+0.02%)

After hours: November 6 at 4:00:43 PM EST

Trade ARWR on Coinbase

Loading Chart for ARWR

Chart Range Bar

Interval:

In partnership with ChartIQ

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

Arrowhead gains UK marketing authorisation for Redemplo

Arrowhead gains UK marketing authorisation for Redemplo

Arrowhead gains UK marketing authorisation for Redemplo

Arrowhead gains UK marketing authorisation for Redemplo

Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own

Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own

Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?

Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study

Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial

Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial

Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know

Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know

Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier

Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Mobilize your Website

View Site in Mobile | Classic

Share by: